# Raymond Evers

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 55 papers | 9,327 citations | 101543 36 h-index | 161849 54 g-index |
| 58 all docs | 58 docs citations | 58 times ranked | 8115 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Assessment of Pharmacokinetic Interaction Between Gefapixant (MKâ€7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin. Clinical Pharmacology in Drug Development, 2022, 11, 406-412. | 1.6 | 6 |
| 2 | Regulation of Drug Transport Proteinsâ€"From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2022, 112, 461-484. | 4.7 | 26 |
| 3 | A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment. Clinical Pharmacology and Therapeutics, 2021, 109, 403-415. | 4.7 | 31 |
| 4 | Protein drug-drug interactions for therapeutic modalities. , 2020, , 387-416. | | 1 |
| 5 | A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery. Drug Metabolism and Disposition, 2020, 48, 1147-1160. | 3.3 | 12 |
| 6 | Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development That Informs Chemically Reactive Metabolite Formation and Potential for Drug-induced Liver Injury. Toxicological Sciences, 2020, 177, 281-299. | 3.1 | 27 |
| 7 | Interindividual and Regional Variability in Drug Transporter Abundance at the Human Bloodâ€"Brain Barrier Measured by Quantitative Targeted Proteomics. Clinical Pharmacology and Therapeutics, 2019, 106, 228-237. | 4.7 | 64 |
| 8 | Use of a Bile Salt Export Pump Knockdown Rat Susceptibility Model to Interrogate Mechanism of Drug-Induced Liver Toxicity. Toxicological Sciences, 2019, 170, 180-198. | 3.1 | 7 |
| 9 | Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. Drug Metabolism and Disposition, 2018, 46, 189-196. | 3.3 | 43 |
| 10 | Transporter expression in non-cancerous and cancerous liver tissue from subjects with hepatocellular carcinoma and chronic hepatitis C infection quantified by LC-MS/MS proteomics. Drug Metabolism and Pharmacokinetics, 2018, 33, S18-S19. | 2.2 | 0 |
| 11 | Diseaseâ€Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2018, 104, 900-915. | 4.7 | 91 |
| 12 | Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions. Journal of Pharmaceutical Sciences, 2017, 106, 2357-2367. | 3.3 | 59 |
| 13 | Antibiotic-induced Elevations of Plasma Bile Acids in Rats Independent of Bsep Inhibition. Toxicological Sciences, 2017, 157, kfx015. | 3.1 | 13 |
| 14 | Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG. Pharmacogenomics, 2016, 17, 615-631. | 1.3 | 4 |
| 15 | The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?. Drug Metabolism and Disposition, 2016, 44, 1498-1509. | 3.3 | 82 |
| 16 | Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics. Drug Metabolism and Disposition, 2016, 44, 1752-1758. | 3.3 | 100 |
| 17 | Quantitative Transporter Proteomics by Liquid Chromatography with Tandem Mass Spectrometry: Addressing Methodologic Issues of Plasma Membrane Isolation and Expression-Activity Relationship. Drug Metabolism and Disposition, 2015, 43, 284-288. | 3.3 | 44 |
| 18 | Establishment of a Hepatocyte-Kupffer Cell Coculture Model for Assessment of Proinflammatory Cytokine Effects on Metabolizing Enzymes and Drug Transporters. Drug Metabolism and Disposition, 2015, 43, 774-785. | 3.3 | 113 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Evaluation of Cynomolgus Monkeys for the Identification of Endogenous Biomarkers for Hepatic Transporter Inhibition and as a Translatable Model to Predict Pharmacokinetic Interactions with Statins in Humans. Drug Metabolism and Disposition, 2015, 43, 851-863. | 3.3 | 55 |
| 20 | Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics. Drug Metabolism and Disposition, 2015, 43, 367-374. | 3.3 | 152 |
| 21 | Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins. Drug Metabolism and Disposition, 2014, 42, 1301-1313. | 3.3 | 31 |
| 22 | Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex. Drug Metabolism and Disposition, 2014, 42, 78-88. | 3.3 | 169 |
| 23 | Pitavastatin is a more sensitive and selective organic anionâ€transporting polypeptide <scp>1B</scp> clinical probe than rosuvastatin. British Journal of Clinical Pharmacology, 2014, 78, 587-598. | 2.4 | 138 |
| 24 | Critical Review of Preclinical Approaches to Investigate Cytochrome P450â€“Mediated Therapeutic Protein Drug-Drug Interactions and Recommendations for Best Practices: A White Paper. Drug Metabolism and Disposition, 2013, 41, 1598-1609. | 3.3 | 68 |
| 25 | In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters. Drug Metabolism and Disposition, 2013, 41, 668-681. | 3.3 | 50 |
| 26 | Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 237-252. | 3.3 | 239 |
| 27 | Characterization of Multidrug Resistance 1a/P-Glycoprotein Knockout Rats Generated by Zinc Finger Nucleases. Molecular Pharmacology, 2012, 81, 220-227. | 2.3 | 48 |
| 28 | Comments on Mougey et al. (2009). Pharmacogenetics and Genomics, 2012, 22, 319-322. | 1.5 | 12 |
| 29 | Determining P-glycoproteinâ€“drug interactions: Evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers. Journal of Pharmacological and Toxicological Methods, 2012, 65, 64-74. | 0.7 | 30 |
| 30 | Membrane transporters in drug development. Nature Reviews Drug Discovery, 2010, 9, 215-236. | 46.4 | 2,886 |
| 31 | In Vitro Techniques to Study Transporter-Based DDI. , 2010, , 237-255. | | 1 |
| 32 | Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes. Nucleic Acids Research, 2009, 37, 1160-1173. | 14.5 | 67 |
| 33 | Metabolism and Renal Elimination of Gaboxadol in Humans: Role of UDP-Glucuronosyltransferases and Transporters. Pharmaceutical Research, 2009, 26, 459-468. | 3.5 | 18 |
| 34 | In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective. Drug Metabolism and Disposition, 2009, 37, 1339-1354. | 3.3 | 152 |
| 35 | Role of the Murine Organic Anion-Transporting Polypeptide 1b2 (Oatp1b2) in Drug Disposition and Hepatotoxicity: Fig. 1.. Molecular Pharmacology, 2008, 74, 309-311. | 2.3 | 38 |
| 36 | Comparison of Immortalized Fa2N-4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P450 Induction. Drug Metabolism and Disposition, 2008, 36, 1046-1055. | 3.3 | 91 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 673-683. | 2.5 | 158 |
| 38 | Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines. Pharmacogenetics and Genomics, 2006, 16, 579-599. | 1.5 | 29 |
| 39 | Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2). Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 579-589. | 2.5 | 129 |
| 40 | Activators of the Rat Pregnane X Receptor Differentially Modulate Hepatic and Intestinal Gene Expression. Molecular Pharmacology, 2004, 65, 1159-1171. | 2.3 | 74 |
| 41 | Transport of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate by the Multidrug Resistance Proteins MRP1, MRP2, and MRP3. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 156-164. | 2.5 | 98 |
| 42 | Chapter 31. Enzyme induction â€" Mechanisms, assays, and relevance to drug discovery and development. Annual Reports in Medicinal Chemistry, 2003, 38, 315-331. | 0.9 | 2 |
| 43 | Role of the N-terminal Transmembrane Region of the Multidrug Resistance Protein MRP2 in Routing to the Apical Membrane in MDCKII Cells. Journal of Biological Chemistry, 2002, 277, 31048-31055. | 3.4 | 65 |
| 44 | Interactions of the Human Multidrug Resistance Proteins MRP1 and MRP2 with Organic Anions. Molecular Pharmacology, 2000, 57, 760-768. | 2.3 | 299 |
| 45 | A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins. Journal of the National Cancer Institute, 2000, 92, 1295-1302. | 6.3 | 1,579 |
| 46 | The multidrug resistance protein family. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1461, 347-357. | 2.6 | 550 |
| 47 | Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochemical Journal, 1999, 338, 393-401. | 3.7 | 232 |
| 48 | Functional Multidrug Resistance Protein (MRP1) Lacking the N-terminal Transmembrane Domain. Journal of Biological Chemistry, 1998, 273, 32167-32175. | 3.4 | 283 |
| 49 | Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Letters, 1997, 419, 112-116. | 2.8 | 130 |
| 50 | Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nature Medicine, 1997, 3, 1275-1279. | 30.7 | 409 |
| 51 | Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP. FEBS Letters, 1996, 391, 126-130. | 2.8 | 55 |
| 52 | Phylogenetic analysis of the RNA polymerases of Trypanosoma brucei, with special reference to class-specific transcription. Current Genetics, 1990, 18, 547-551. | 1.7 | 8 |
| 53 | TheTrypanosoma bruceiprotein phosphatase gene: polycistronic transcription with the RNA polymerase II largest subunit gene. Nucleic Acids Research, 1990, 18, 5089-5095. | 14.5 | 29 |
| 54 | Unusual C-terminal domain of the largest subunit of RNA polymerase II ofCrithidia fasciculata. Nucleic Acids Research, 1989, 17, 3403-3413. | 14.5 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Trypanosoma brucei contains two RNA polymerase II largest subunit genes with an altered C-terminal domain. Cell, 1989, 56, 585-597. | 28.9 | 125 |